G V R Krishna Prasad

Dr. G V R Krishna Prasad

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
EMEkansh Mittal
Ekansh Mittal
GPG V R Krishna Prasad
G V R Krishna Prasad
SUSandeep Upadhyay
Sandeep Upadhyay
JSJully Sadadiwala
Jully Sadadiwala
AOAndrew Olive
Andrew Olive
JPJennifer Philips
Jennifer Philips

23 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GPG V R Krishna Prasad
G V R Krishna Prasad
SGSteven J. Grigsby
Steven J. Grigsby
GEGideon A. Erkenswick
Gideon A. Erkenswick
CPCynthia Portal-Celhay
Cynthia Portal-Celhay
EMEkansh Mittal
Ekansh Mittal
JPJennifer Philips
Jennifer Philips
CD4+ T cells are crucial for protective immunity to intracellular pathogens. In addition to secreting cytokines, CD4+ T cells promote control of Mycobacterium tuberculosis infection through cognate interactions with macrophages, but the mechanism has been unclear. Here, we show that SLAMF1/CD150 is highly and uniquely induced in macrophages by antigen-specific interactions with CD4+ T cells. In macrophages, SLAMF1 enhances the generation of reactive oxygen species and restricts Mtb replication. Mtb-infection of mice promotes SLAMF1 expression specifically on infected macrophages, not uninfected bystanders. SLAMF1 expression depends on adaptive immunity and also autophagy. Moreover, Slamf1−/− mice have higher Mtb burden and more rapid disease progression than wild type mice. Using Slamf1fl/fl conditional knock-out mice, we show that in vivo Slamf1 is specifically required in macrophages to restrict mycobacterial growth and limit IL-1β production. In macaques, macrophage SLAMFI expression also correlates with T cell responses and protection. Combined, these data demonstrate that SLAMF1 is a marker of macrophage-T cells interactions, and it promotes protection against Mtb.

2 May 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
GPG V R Krishna Prasad
G V R Krishna Prasad
JPJennifer Philips
Jennifer Philips
Globally, Mycobacterium tuberculosis (Mtb) remains the leading cause of death from a single infectious agent. The only licensed vaccine, Bacillus Calmette–Guérin (BCG), was developed over a century ago and does not provide consistent protection against pulmonary tuberculosis (TB). Efforts to develop more effective vaccines are hindered by an incomplete understanding of the correlates of protection and by the pathogen’s sophisticated immune-evasion strategies. Mtb systematically undermines host defenses, reprograms host cell biology, and interferes with cell–cell communication to establish a permissive niche and sustain chronic infection. An effective vaccine must elicit immune responses capable of overcoming these bacterial strategies across diverse host and pathogen backgrounds. Traditional approaches focused on boosting T cell responses have proven inadequate. In this review, we summarize innate and adaptive immune mechanisms that contain Mtb, examine how bacterial immune subversion and host–pathogen heterogeneity complicate vaccine design, and highlight emerging concepts and strategies to guide TB vaccine development.